ATRIAL-NATRIURETIC-PEPTIDE AND PLASMA-RENIN LEVELS IN ASSESSMENT OF MINERALOCORTICOID REPLACEMENT IN ADDISONS-DISEASE

Citation
N. Cohen et al., ATRIAL-NATRIURETIC-PEPTIDE AND PLASMA-RENIN LEVELS IN ASSESSMENT OF MINERALOCORTICOID REPLACEMENT IN ADDISONS-DISEASE, The Journal of clinical endocrinology and metabolism, 81(4), 1996, pp. 1411-1415
Citations number
25
Categorie Soggetti
Endocrynology & Metabolism
ISSN journal
0021972X
Volume
81
Issue
4
Year of publication
1996
Pages
1411 - 1415
Database
ISI
SICI code
0021-972X(1996)81:4<1411:AAPLIA>2.0.ZU;2-3
Abstract
Assessment of mineralocorticoid replacement therapy in Addison's disea se relies on clinical features and laboratory measurements, including plasma renin and potassium. Previous studies have questioned the value of measuring the plasma renin concentration (PRC), particularly in th e setting of fludrocortisone overreplacement. The aim of this study wa s to evaluate the usefulness of plasma atrial natriuretic peptide (ANP ) measurements as a marker of sodium and volume status in Addison's di sease. Fourteen patients with Addison's disease receiving their usual glucocorticoid doses were placed on various doses of fludrocortisone ( FC; 0 mg, 0.05 mg, 0.1 mg and 0.2 mg) in random order for four 2-week periods. At the end of each period, blood pressure and clinical sympto ms were assessed, and blood was drawn for measurement of PRC and ANP l evels. PRC was significantly elevated in patients receiving placebo (5 4.2 +/- 57.9 ng/mL . h) compared with PRC in those receiving baseline FC (24.7 +/- 42.4 ng/ml . h), 0.1 mg FC (15.2 +/- 25.9 ng/mL . h), and 0.2 mg FC (5.5 +/- 5.7 ng/mL . h). ANP levels were measured by either an extraction method (ANP((ext)) or directly from plasma (ANP((dir)). ANP((dir)) was significantly elevated at 0.2 mg FC (87.1 +/- 20.1 pg/ mL) compared with baseline (63.3 +/- 8.1 pg/mL), placebo (56.1 +/- 5.5 pg/mL), 0.05 mg FC (60.5 +/- 16.0 pg/mL), and 0.1 mg FC (65.4 +/- 13. 7 pg/mL) values. ANP((ext)) was elevated in patients receiving 0.2 mg FC (42.7 +/- 41.8 pg/mL) compared with that in patients receiving plac ebo (7.9 +/- 5.4 pg/mL), 0.05 mg FC (16.2 +/- 11.2 pg/mL), or 0.1 mg F C (19.7 +/- 11.1 pg/mL). Our data suggest that PRC is of value in dete rmining mineralocorticoid underreplacement, whereas ANP is a more sens itive index of FC overreplacement. ANP levels may, therefore, be compl ementary to PRC in adjustment of mineralocorticoid doses in the upper dose range, where clinical symptoms and signs appear to be of little v alue.